A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

NCT01716806 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Disease
Peripheral T Cell Lymphoma

Interventions

DRUG: brentuximab vedotin
DRUG: bendamustine
DRUG: dacarbazine
DRUG: nivolumab

Sponsor

Seagen Inc.

Collaborators

[object Object]